SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC (EIN 850837695) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2020

Legal Domicile

Principal Officer

DONNA FRENCH

Phone

5036190505

Tax Period

2024-01-01 to 2024-12-31

SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC, founded in 2020, is a small nonprofit in the Community Improvement sector that reported $720K in total revenue in fiscal year 2024. Revenue decreased 5% compared to the prior year. The organization ran a surplus of $228K, a strong 32% operating margin.

Mission

OUR MISSION IS TO COLLABORATIVELY ADVANCE THE MOST PRESSING ISSUES AND OPPORTUNITIES IN SUBCUTANEOUS DOSAGE AND DELIVERY IN A PRECOMPETITIVE MANNER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $721,667

Investment Income $-1,944

Other Revenue $0

TOTAL REVENUE $719,723

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Other Expenses $491,843

TOTAL EXPENSES $491,843

Year-over-Year Comparison

	2024	2023	Change
Revenue	$719,723	$760,000	-0.1%
Expenses	$491,843	$769,199	-0.4%
Net Income	$227,880	$-9,199	-25.8%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DONNA FRENCH	PRESIDENT	5.00	Officer Director	$0	$0	$0
SACHIN MITTAL	VICE PRESIDE	5.00	Officer Director	$0	$0	$0
DAVID KANG	TREASURER	5.00	Officer Director	$0	$0	$0
MONICA ADAMS	DIRECTOR	5.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$719,723	$491,843	$1,156,608	$227,880
2023	$760,000	$769,199	$901,226	$-9,199
2022	$406,250	$537,991	$685,644	$-131,741
2021	$600,000	$280,411	$868,101	$319,589
2020	$500,000	$53,145	$726,531	$446,855

SUBCUTANEOUS DRUG DEVELOPMENT & DELIVERY CONSORTIUM INC